These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30843181)

  • 1. Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology.
    Bolanowski M; Ruchała M; Zgliczyński W; Kos-Kudła B; Hubalewska-Dydejczyk A; Lewiński A
    Endokrynol Pol; 2019; 70(1):2-18. PubMed ID: 30843181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acromegaly--a novel view of the patient. Polish proposals for diagnostic and therapeutic procedures in the light of recent reports.
    Bolanowski M; Ruchała M; Zgliczyński W; Kos-Kudła B; Bałdys-Waligórska A; Zieliński G; Bednarczuk T; Hubalewska-Dydejczyk A; Kamiński G; Marek B; Daroszewski J; Waśko R; Lewiński A
    Endokrynol Pol; 2014; 65(4):326-31. PubMed ID: 25185857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline in acromegaly.
    Kuhn E; Chanson P
    Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M
    Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
    Ciresi A; Radellini S; Guarnotta V; Giordano C
    BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
    Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
    Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
    Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
    Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimization of the medical treatment for acromegaly].
    Díez JJ; Iglesias P
    Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic management of acromegaly].
    Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
    Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP).
    Brue T; Rahabi H; Barry A; Barlier A; Bertherat J; Borson-Chazot F; Castinetti F; Cazabat L; Chabre O; Chevalier N; Christin-Maitre S; Cortet C; Drui D; Kamenicky P; Lançon C; Lioté F; Pellegrini I; Reynaud R; Salenave S; Tauveron I; Touraine P; Vantyghem MC; Vergès B; Vezzosi D; Villa C; Raverot G; Coutant R; Chanson P; Albarel F
    Ann Endocrinol (Paris); 2023 Dec; 84(6):697-710. PubMed ID: 37579837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
    Neggers SJ; van der Lely AJ
    Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 2: Therapeutic Issues.
    Cozzi R; Ambrosio MR; Attanasio R; Bozzao A; De Marinis L; De Menis E; Guastamacchia E; Lania A; Lasio G; Logoluso F; Maffei P; Poggi M; Toscano V; Zini M; Chanson P; Katznelson L
    Endocr Metab Immune Disord Drug Targets; 2020; 20(8):1144-1155. PubMed ID: 31995025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegvisomant: new preparation. A last resort in acromegaly.
    Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second line treatment of acromegaly: Pasireotide or Pegvisomant?
    Chiloiro S; Bianchi A; Giampietro A; Pontecorvi A; Raverot G; Marinis L
    Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101684. PubMed ID: 35931640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pasireotide (SIGNIFOR) in acromegaly. After treatment failure: better than pegvisomant.
    Prescrire Int; 2016 Feb; 25(168):38-9. PubMed ID: 27042726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
    Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.